All preclinical study estimates are not created equal: they may or may not include line items that can widely influence the total fee.
We know preclinical studies are expensive. Medical product innovators need to know much more goes into the making of a high quality, value-based preclinical study that is critical, but is not always obvious.
What costs should you expect, and what should you watch out for, when planning your next preclinical study?
Join GCMI CFO Jeffrey White, Preclinical Program Manager Matthew Elder, and Preclinical Program Director Deepal Panchal for a 30 minute webinar on Thursday, June 18 at 11:00 a.m. EDST. They will help you understand what’s needed – and frequently missing – in preclinical study estimates to properly plan, budget, get it right the first time and give your product the best chance of getting to through preclinical and into regulatory submission.